The heads of the FDA and NIH co-authored a letter acknowledging the therapeutic potential of LSD, MDMA, psilocybin, and ketamine.
The heads of the Food and Drug Administration (FDA) and the National Institutes of Health (NIH) have acknowledged the therapeutic potential of psychedelic drugs ranging from LSD to ketamine in a letter discussing the status of research on these drugs in the US.
The letter was written in response to an inquiry from Hawaii Senator Brian Schatz, who asked whether the government had plans to research or approve psychedelic drugs for medical use. In his letter, Schatz wrote that “studies have found the benefits of the controlled use of psychedelics in psychotherapy programs, including the benefits of lysergic acid diethylamide (LSD) to reduce anxiety for patients with life-threatening diseases, and the safety and efficacy of ketamine, MDMA, psilocybin, LSD, and ibogaine in clinical trials.”
Quelle: The Feds Finally Admit That Psychedelics Are Medicine